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ACE = angiotensin converting enzyme
ANP = atrial natriuretic peptide
BNP = brain natriuretic peptide
cAMP = cyclic adenosine monophosphate
CHF = chronic heart failure
CPT = carnitine palmitoyl transpherase
DHEA = dehydroepiandrosterone
DHEAS = dehydroepiandrosterone sulfate
ECG = electrocardiogram
FetCO2 = end-tidal carbon dioxide fraction
FFA = free fatty acid
HF = high frequency
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NYHA = New York Heart Association
PFK = phosphofructokinase
PHRL = phophorylase
PHRLa = active phosphorylase
RAA = renin-angiotensin-aldosterone
SHBG = sex hormone binding globulin
TNF-α = tumor necrosis factor -α
VCO2 = carbon dioxide production
VCO2/VO2 = respiratory exchange ratio
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1. INTRODUCTION
Chronic heart failure (CHF) is becoming the
greatest challenge in cardiovascular care.
CHF greatly impairs the quality of life of
the patients by limiting their exercise capac-
ity through dyspnea and muscle fatigue.
Quality of life is impaired more than in any
other common chronic medical disorder
(Stewart et al. 1989). CHF is associated with
frequent hospitalizations and high mortali-
ty due to worsening pump failure or sudden
death. The number of hospital disharges has
been reported to double every ten years both
in Europe and the United States  (Cowie et
al. 1997). In 1990, heart failure was the most
frequent first-listed diagnosis for hospital
discharges in people older than 65 years, and
it was the third most important reason for
in-patient days in the hospital (Eriksson
1995). The main reason for the increasing
burden of CHF is the ageing population.
Another important cause is the improved
survival from acute myocardial infarction.
The increased knowledge of the patho-
physiology of CHF, particularly the discov-
ery of the central role of the neurohormo-
nal and cytokine activation (Packer 1992),
has resulted in significant progress in the
care of the patients. ACE inhibition and β-
blockade were the first medical interven-
tions shown to reduce mortality (The CON-
SENSUS Trial Study Group 1987, CIBIS-
II Investigators and Committees 1999). Be-
sides this, the observations of significant
changes in the periphery, especially in skel-
etal muscle and peripheral circulation (Wil-
son et al. 1984, Drexler 1992a), aroused in-
terest in re-evaluating the effects of exer-
cise in the care of patients with CHF.
Until the end of the 1980s, patients with
CHF were advised to avoid physical exer-
cise for fear of further weakening the heart.
In recognizing that CHF is not purely a fail-
ure of the heart pump but a syndrome with
notable peripheral abnormalities, the hy-
pothesis arose that physical training can im-
prove exercise capacity and alleviate symp-
toms by reversing the peripheral changes. It
can also be assumed that for many of the
CHF patients, a neutral effect of training,
i.e. neither beneficial nor harmful, would be
positive, because merely allowing patients
who have been told to avoid physical activ-
ity to exercise would probably improve their
quality of life.
Three prospective studies, two uncon-
trolled and one crossover study, had been
published about the effect of physical train-
ing on CHF patients before this study be-
gan (Lee et al. 1982, Sullivan et al. 1988a,
Coats et al. 1990). The purpose of this study
was to show in a randomized and control-
led protocol that physical training improves
exercise capacity in these patients and, ad-
ditionally, has a beneficial effect on the de-
rangements in the autonomic nervous sys-
tem, a prognostic marker, and on the chang-
es in skeletal muscle.
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2. REVIEW OF THE LITERATURE
2.1. Chronic heart failure
syndrome
2.1.1. Definition and diagnosis
Heart failure has been defined as a failure
of the heart to maintain adequate perfusion
to meet the requirements of the metaboliz-
ing tissues at rest and/or during exercise in
spite of normal blood volume. However, the
clinical diagnosis of CHF requires evidence
of ventricular dysfunction at rest and the
presence of typical symptoms, dyspnea and/
or muscle fatigue at rest or during exercise
(Task Force on Heart Failure of the Euro-
pean Society of Cardiology 1995). CHF is
caused by the failure of the systolic func-
tion, diastolic function or both. The failure
of the systolic function is due to the incapa-
bility of the myofibrils to shorten adequate-
ly and/or to a critical loss of myocardial
mass. The diastolic failure means inadequate
filling of the ventricle in spite of sufficient
atrial pressure, which can be due to impaired
relaxation or reduced passive elasticity of
the ventricle. The impaired relaxation is
usually a consequence of myocardial ischae-
mia or ventricular hypertrophy. Among the
main causes of a reduction of elasticity are
ageing-related fibrosis, infiltrative myocar-
dial diseases, diabetes and pericardial dis-
eases (Vasan et al. 1995).
2.1.2. Incidence and prevalence
The age-unadjusted incidence of CHF in the
general population ranges from 1.0 to 5.0
per 1000 people per year (Cowie et al. 1997).
However, there is a steep increase with ad-
vancing age. The incidence in men and
women from 45 to 54 years of age is 2 and
1 cases per 1000 people per year, respec-
tively, but rises to 54 and 85 cases, respec-
tively between 75 and 84 years of age (Kan-
nel et al. 1991, Kannel et al. 1994). The prev-
alence estimates vary widely from 3 to 20
individuals per 1000 in the whole popula-
tion and from 30 to 130 individuals per 1000
in the age group older than 65 years (Cowie
et al. 1997). In addition to age, the lack of a
generally accepted definition and difficulty
in the diagnosis of CHF explain the wide
variation in these figures.
Coronary heart disease is the most com-
mon cause of CHF. Its age-adjusted propor-
tion has increased from 22% in the 1950s
to 67% in the 1980s (Ho et al. 1993). The
other major aetiological factor is hyperten-
sion, often together with coronary heart dis-
ease (Remes et al. 1992, Ho et al. 1993).
The proportion of valvular heart disease has
been markedly decreasing. In approximately
90% of cases, CHF is due to these factors.
The proportion of coronary heart disease as
an aetiological factor rises with age but es-
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pecially in old people, CHF is a multifacto-
rial syndrome (Kupari et al. 1997).
2.1.3. Prognosis
The prognosis of untreated CHF is unknown
because all the patient information dates
from the time of medical treatment. How-
ever, CHF has a poor prognosis in spite of
medication. In the Framingham study, the
median survival after a 90-day history of
heart failure was 3.2 years in men and 5.4
years in women (Ho et al. 1993). The same
study showed that the survival was not bet-
ter during the period 1975-1988, preceding
the era of the widespread use of ACE-in-
hibitors, compared with an earlier period
1948-1974. In the United States, the mor-
tality from CHF increased four-fold during
the 1970s and 1980s while that from other
major cardiovascular causes decreased (Yu-
suf et al. 1989).
However, ACE inhibition has been con-
sistently shown to reduce mortality and
morbidity. The CONSENSUS trial report-
ed that in patients in NYHA class IV there
was a mortality of 36% in one year with
enalapril added to the conventional treat-
ment, but it exceeded 50% in the placebo
group (The CONSENSUS Trial Study
Group 1987). In the treatment arm of the
SOLVD trial, in which nearly 90% of the
patients both in the placebo and the enal-
april group were in NYHA classes II and
III, there was a mortality of 40% in four
years in the former group and of 35% in the
latter (SOLVD Investigators 1991). Recent-
ly, two large studies have demonstrated that
β1 -selective blockade reduces mortality by
approximately 30-35% on top of ACE inhi-
bition. In the MERIT-HF trial, the mortali-
ty in the metoprolol group was 5.3% per year
in NYHA class II and 16.7% in NYHA class
IV (MERIT-HF Study Group 1999). The
majority of deaths in mild and moderate
CHF are sudden (MERIT-HF Study Group
1999), usually caused by ventricular ar-
rhythmias (Stevenson 1995). In severe CHF,
the most common cause of death is worsen-
ing heart failure.
2.1.4. Pathophysiology (Fig. 1)
2.1.4.1. Neurohormonal activation
The origin of CHF is worsened ventricular
function as an end-result of various cardiac
diseases leading to failure to maintain an
adequate perfusion of the metabolizing tis-
sues. Traditionally, it has been regarded as
a pure haemodynamic disorder, the severi-
ty of which has been described by the size
of the heart, cardiac output and central
haemodynamic pressures. However, haemo-
dynamic abnormalities have not sufficient-
ly explained the progression of heart fail-
ure and, furthermore, therapeutic strategies
designed to correct haemodynamic derange-
ments have had an adverse effect on the
long-term outcome of the patients (Franci-
osa et al. 1984, Packer et al. 1991). At this
time, there is mounting evidence that the
complex neurohormonal and cytokine acti-
vation encountered in CHF better explains
these issues that have remained unanswered
by the haemodynamic hypothesis (Packer
1992).
The sympathetic nervous system is acti-
vated early in CHF. The activation has been
shown by an increased nerve traffic in per-
oneal microneurographic recordings (Leim-
bach et al. 1986), by an elevation in the plas-
14
Figure 1.
Central pathophysiologic mechanisms in chronic heart failure. Solid lines between the
figures indicate a known effect and the broken lines a possible effect. The arrowheads
pointing upwards inside the figures indicate an increase and those pointing downwards a
decrease. See text.
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ma noradrenaline level (Chidsey et al. 1962)
and by increased noradrenaline spillover
into plasma (Hasking et al. 1986). Cardiac
adrenergic drive is the first to be increased
preceding the generalized sympathetic ac-
tivation (Rundqvist et al. 1997).
Sympathetic activation improves cardiac
inotropy and enhances vasoconstriction, and
thus maintains cardiac output and blood
pressure. The mechanism has been attribut-
ed to blunted inhibitory input from the arte-
rial and cardiopulmonary baroreceptors. The
baroreflex control has been demonstrated to
be severely impaired already in patients with
mild heart failure (Grassi et al. 1995). The
impairment also attentuates the parasympa-
thetic control on heart rate (Floras 1993).
Excitatory input to sympathetic outflow is
increased by augmented chemoreceptor sen-
sitivity (Chua et al. 1996) and accentuated
ergoreflex in exercising skeletal muscle
(Piepoli et al. 1996), but these abnormali-
ties are suggested to appear later (Middle-
kauff 1997). An elevated plasma noradren-
aline level, decreased heart rate variability
(HRV) and attenuated baroreflex sensitivi-
ty have all been shown to predict mortality
in CHF (Cohn et al. 1984, Nolan et al. 1998,
Osterziel et al. 1995)
The activation of the sympathetic nerv-
ous system together with a decrease in blood
pressure and renal blood flow induces the
activation of the renin-angiotensin-aldoster-
one (RAA) -system (Curtiss et al. 1978),
which augments vasoconstriction, reduces
the glomerular filtration rate and promotes
sodium retention. In addition, angiotensin
II stimulates vasopressin and endothelin
secretion, the plasma levels of which are
elevated in CHF (Yamane 1968, Lerman et
al. 1992). Vasopressin further augments
water retention and vascular resistance. En-
dothelin is an endothelium-derived potent
vasoconstrictor (Yanagisawa et al. 1988). It
has been suggested that in CHF the humor-
al RAA-system is not activated until the
symptomatic phase or during diuretic ther-
apy, but the local RAA-system is already
activated during the asymptomatic phase
(Hirsch et al. 1990). The stimulation of lo-
cal noradrenaline release by angiotensin II
emphasizes the interaction of these two neu-
rohormonal systems.
The crucial feature in CHF is the persist-
ance of the neurohormonal activation which
turns from adaptive to maladaptive and be-
comes deleterious leading to the progres-
sion of CHF. The concomitant activation of
counteracting vasodilatory and natriuretic
substances, ANP (Burnett et al. 1986), BNP
(Mukoyama et al. 1990) and adrenomedul-
lin (Nishikimi et al. 1995) with the increased
secretion of vasodilatory prostaglandins
(Dzau et al. 1984) is insufficient to reverse
it.
In advanced phases of CHF, an activation
of tumor necrosis factor-α (TNF-α) has
been demonstrated (Levine et al. 1990), and
this both locally and systemically affecting
cytokine, appears to be a significant media-
tor in the process of CHF, and elevated plas-
ma levels of TNF-α are known to predict
mortality in this syndrome (Marriott et al.
1996).
2.1.4.2. Heart muscle
The crucial process in the myocardium in
CHF is remodelling (Spinale 1999), and
according to mounting evidence, this remod-
elling process is mediated by the factors in-
volved in the neurohormonal activation.
Noradrenaline, angiotensin II and endothe-
lin-1 together with mechanical stretch in-
duce hypertrophy of cardiac myocytes and
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interstitial cells, and the RAA-system has
been shown to stimulate fibrosis in advanced
heart failure (Baig et al. 1998). Ventricular
hypertrophy is an attempt to preserve pump
function, but with excess fibrosis, both the
systolic and diastolic functions are impaired.
On the other hand, hypertrophy lengthens
the QT interval in cardiac myocytes, which
may be one reason for the increased risk of
sudden arrhythmogenic death occurring
even in mild heart failure (Stevenson et al.
1997).
The elevated noradrenaline concentration
at cardiac receptor sites also results in re-
sistance to the beneficial haemodynamic
actions of catecholamines through β-recep-
tor downregulation / desensitization (Bristow
et al. 1982).
Programmed cell death, apoptosis, and
disruption of the fibrillar collagen network,
providing the structural integrity to adjoin-
ing myocytes, also seem to be important
mechanisms contributing to the progression
of pump failure through myocardial cell loss
and discoordination of myocyte shortening
(Anversa et al. 1996, Spinale 1999). Pro-
grammed cell death is not restricted to my-
ocytes but affects interstitial fibroblasts as
well (Anversa et al. 1996). The cleavage of
the fibrillar collagen network is mediated
through the increased activity of matrix
metalloproteinases, which are a family of
endogenous enzymes responsible for matrix
remodelling in a number of physiological
and pathological conditions (Mann et al.
1998). This activation is associated with the
reduced activity of the tissue inhibitors of
the metalloproteinases (Li et al. 1998).
Again, the importance of neurohormonal
and cytokine activation in the pathophysi-
ology of CHF is emphasized by the finding
that noradrenaline and TNF-α have been
found to induce and mediate apoptosis
(Colucci 1996) and the increased expression
of the matrix metalloproteinases (Spinale
1999).
2.1.4.3. Peripheral blood flow
The interest in peripheral tissues in CHF has
been aroused by the finding that indices of
left ventricular function and central haemo-
dynamics at rest correlate poorly with symp-
toms and exercise capacity (Franciosa et al.
1981, Szlachcic et al. 1985). Furthermore,
interventions that acutely improve central
haemodynamics, including heart transplan-
tation, do not lead to an immediate improve-
ment in exercise capacity (Massie et al.
1981, Maskin et al. 1983, Sinoway et al.
1988).
 Peripheral blood flow does not increase
adequately during exercise in patients with
CHF (Zelis et al. 1982), and the blood flow
to the exercising leg is reduced (Wilson et
al. 1984). This is not due to hypotension
during exercise (Sullivan et al. 1989a), rather
the arteriolar vasodilatation is impaired (Ze-
lis et al. 1968, LeJemtel et al. 1986), and
leg vascular resistance is higher (Sullivan
et al. 1989a) compared with healthy sub-
jects. The increased resistance seems to be
due to an increased vasoconstrictory effect
through the activation of the sympathetic
nervous system (Thomas et al. 1978), RAA
system (Curtiss et al. 1978, Dzau et al. 1981
and elevated levels of circulating plasma en-
dothelin (McMurray et al. 1992). At the same
time, nitrous oxide -dependent vasodilata-
tion is impaired because of endothelial dys-
function (Kubo et al. 1991, Katz et al. 1992).
In addition, sodium and fluid retention can
stiffen vessel walls and cause perivascular
compression (Sinoway et al. 1987). These
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factors overcome the vasodilatory effects of
increased concentrations of ANP, BNP and
adrenomedullin. Abnormal blood rheology
(Siostrzonek et al. 1992) and increased
thickness of the skeletal muscle capillary
basement membrane (Longhurst et al. 1975)
may further contribute to inadequate blood
supply in metabolizing tissues.
2.1.4.4. Lungs and ventilation
Most studies have demonstrated a restric-
tive pattern of airway dysfunction in patients
with CHF, which seems to be due to en-
larged heart, stiffening of the lung paren-
chyma and the presence of chronically flu-
id-filled alveolar spaces (Chua et al. 1995a).
Minute ventilation (VE) is increased per se
and also in relation to carbon dioxide pro-
duction (VCO2) both at rest and during ex-
ercise (Sullivan et al. 1988b, Sovijärvi et al.
1992). The ventilatory equivalent for car-
bon dioxide (VE/VCO2) correlates inverse-
ly with the exercise capacity measured by
peak VO2 (Sovijärvi et al. 1992). The stim-
ulus of the excessive ventilation remains
unclear. Ventilation-perfusion mismatch
with increased dead-space ventilation (So-
vijärvi et al. 1992, Wasserman et al. 1997),
increased hypoxic chemosensitivity (Chua
et al. 1996) and exaggerated ergoreflex ac-
tivity in skeletal muscles (Piepoli et al. 1996)
have been proposed as the mechanism. There
is no correlation with pulmonary artery pres-
sures or pulmonary capillary wedge pressure
at rest or during exercise (Fink et al. 1986,
Sullivan et al. 1988b). Pulmonary diffusion
is impaired at rest and during exercise (Smith
et al. 1999) but arterial oxygen desaturation
is lacking (Rubin et al. 1982).
The sensation of dyspnea in CHF is sug-
gested to originate from the increased work
of breathing, owing to excessive ventilation,
increased breathing resistance and de-
creased lung compliance (Mancini 1995).
In addition, inspiratory and expiratory mus-
cle strength and respiratory muscle endur-
ance have been shown to be reduced (Chua
et al. 1995b, Mancini et al. 1994). The re-
duction may be connected with underper-
fusion of accessory respiratory muscles
demonstrated with near-infrared spectros-
copy (Mancini et al. 1991).
2.1.4.5. Skeletal muscle
Impaired exercise endurance and early
anaerobic metabolism with prolonged met-
abolic recovery time are the major function-
al abnormalities of skeletal muscle in CHF
(Wilson et al. 1985, Mancini et al. 1988,
Minotti et al. 1991). Skeletal muscle biop-
sies have shown that lactate accumulates and
direct energy sources, adenosine triphos-
phate and phosphocreatine, deplete rapidly
during exercise (Näveri et al. 1997). Maxi-
mal strength of skeletal muscle is reduced
in patients with CHF due to muscle wast-
ing but strength per unit muscle has been
reported to be normal (Minotti et al. 1991)
or reduced (Harrington et al. 1997).
The abnormal function of skeletal mus-
cle is associated with abnormalities in mus-
cle histology and metabolism. Significant
atrophy and variance in muscle fibre size
have been encountered (Lipkin et al. 1988,
Mancini et al. 1992). The proportion of
slow-twitch, type I aerobic fibres, has been
reported to be lower in CHF patients com-
pared with healthy subjects in some (Sulli-
van et al. 1990, Massie et al. 1996) but not
in all studies (Mancini et al. 1989). On the
.
.
. .
.
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other hand, the proportion of fast-twitch,
type II anaerobic fibres, is increased, which,
according to some results, is mainly due to
an increase in the proportion of type IIb fi-
bres (Mancini et al. 1989, Sullivan et al.
1990, Drexler et al. 1992b). The muscle cap-
illary density (capillarity per fibre) has been
found to be normal (Mancini et al. 1989) or
reduced (Sullivan et al. 1990, Drexler et al.
1992b). Within the muscle fibres, the vol-
ume density of mitochondria and the sur-
face density of mitochondrial cristae are
reduced, which is associated with lower
peak VO2 (Drexler et al. 1992b).
The activities of the citric acid cycle en-
zymes have been found to be reduced (Sul-
livan et al. 1990, Näveri et al. 1997) or nor-
mal (Mancini et al. 1989), but those of the
fatty acid oxidation enzymes uniformly re-
duced (Mancini et al. 1989, Sullivan et al.
1990, Näveri et al. 1997). One study showed
a reduction in the activity of phosphofruc-
tokinase (Sylvén et al. 1991), but in other
studies, no significant change in its activity
or in that of other enzymes of the glycolytic
pathway has been observed (Mancini et al.
1989, Sullivan et al. 1990, Näveri et al.
1997).
Recent results show that expression of
inducible nitric oxide synthase, iNOS, is
increased in the skeletal muscle of patients
with CHF, correlating inversely with exer-
cise capacity (Hambrecht et al. 1999). In-
creased levels of intracellular nitric oxide
were associated with a reduced expression
of mitochondrial creatine kinase, which
implies a reduction of high-energy phos-
phate transfer from mitochondria to cytosol
(Adams et al. 1997, Hambrecht et al. 1999).
Furthermore, apoptosis has been observed
in skeletal muscle correlating with more
depressed peak VO2 and long duration of
CHF (Adams et al. 1999).
The causes of skeletal muscle abnormal-
ities in patients with CHF are not clear. Re-
duced blood flow (Drexler 1992a) has been
suggested. On the other hand, the early pH
decrease and phosphocreatine depletion
during exercise have been shown to be in-
dependent of blood flow in a forearm mus-
cle (Wiener et al. 1986, Massie et al. 1987),
which has been demonstrated even during
circulatory occlusion (Massie et al. 1988).
These findings have been regarded as evi-
dence of an intrinsic muscle abnormality.
Inactivity per se can be another explanation
for the abnormalities in muscle function
(Chati et al. 1996). The catabolic effect of
the neurohormonal factors and cytokines
and protein-energy malnutrition have also
been proposed (Levine et al. 1990, Anker et
al. 1997a, Schwengel et al. 1994). Howev-
er, the abnormal muscle fatigue does not
seem to be caused by impaired central mo-
tor drive or an abnormal neuromuscular
junction transmission (Minotti et al. 1992,
Harridge et al. 1996).
2.2. Physical training in
healthy subjects
Training improves maximal VO2 in young
sedentary subjects 10-30% (Clausen 1976).
This is due to an increase in maximal cardi-
ac output and an improvement in arterio-
venous oxygen difference in trained extrem-
ities, which explains approximately 50% of
the rise in maximal VO2 (Clausen 1976).
Training reduces heart rate during submax-
imal exercise but does not affect maximal
heart rate. The reduction is generally ex-
plained to be secondary to an increase in
stroke volume, but adaptations in trained
muscles seem to contribute (Clausen 1976).
.
.
.
.
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VE diminishes at submaximal exercise with
a decrease in breathing frequency but increas-
es at maximal exercise. Furthermore, venti-
latory equivalent for oxygen (VE/VO2) is re-
duced during exercise with a delayed rise in
the respiratory exchange ratio (VCO2/VO2)
(Clausen 1976).
 Training reduces blood flow to active
muscles at submaximal workloads, and
there is a concomitant rise in arterio-venous
oxygen difference. During maximal exer-
cise, blood flow is increased (Clausen et al.
1973). Endurance training increases the
number of capillaries per fibre area (How-
ald 1982). An increase in mitochondria and
the enzyme activities of fatty acid oxidation,
the Krebs cycle and the respiratory chain in
skeletal muscle cells is of primary impor-
tance (Holloszy et al. 1984). The glycolytic
enzyme activities seem to decrease in en-
durance training but increase in anaerobic
and strength training (Howald 1982).
It has been widely thought that the fibre-
type distribution is genetically determined
and can not be changed (Howald 1982).
However, endurance training can change the
percentage distribution between the sub-
types of type II fibres, from type IIb to IIa,
the latter of which has a higher oxidative
capacity (Holloszy et al. 1984). Whether
fast-twitch fibres can be converted to slow-
twitch fibres by training has not been shown.
There are reports of a few cases in humans
suggesting that immobilization may lead to
the opposite transformation (Häggmark et
al. 1981).
Training has a beneficial effect on the
function of the autonomic nervous system
in healthy subjects. It increases parasympa-
thetic modulation of HRV (Goldsmith et al.
1992) and even a single intensive dynamic
exercise session has been reported to im-
prove baroreflex sensitivity (Convertino et
al. 1991).
Age is not a hindrance in receiving bene-
ficial effects from exercise training. One
study reported an improvement in peak VO2
in elderly people that was comparable to that
in younger people (Blumenthal et al. 1991).
The maintenance of regular aerobic train-
ing also appears to improve the anaerobic
threshold more than peak VO2 which points
to a better capacity to work at submaximal
work loads (Blumenthal et al. 1991).
2.3. Physical training in
chronic heart failure
2.3.1. History
Evaluation of physical training in patients
with a history of myocardial infarction start-
ed in the 1960s, but the first study that in-
cluded patients with impaired left ventricu-
lar function was not published until 1979
(Lee et al.). The findings showed an im-
provement in exercise capacity without a
change in resting haemodynamic or ven-
triculographic parameters. The retrospective
study by Conn et al. supported these results
(1982). Fioretti et al. (1987) showed later
that predischarge data from invasive haemo-
dynamic monitoring and exercise testing
after a recent myocardial infarction do not
predict who would benefit from a training
programme. They concluded that exclusion
from training on the basis of haemodynam-
ics, left ventricular ejection fraction or ST-
segment depression was not justified.
The first study that included patients with
CHF due to non-ischaemic cardiomyopathy
was published in 1988 (Sullivan et al.
. .
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1988a). In this uncontrolled study, exercise
training of 3-5 hours per week for 4-6
months at a heart rate corresponding to 75%
of peak VO2 resulted in a 23% increase in
peak VO2, a significant increase in leg blood
flow and a decrease in leg vascular resist-
ance at peak exercise. Training also caused
an increasing trend in maximal cardiac out-
put. The randomized crossover study by
Coats et al. (1990) confirmed the beneficial
effect of physical training on exercise ca-
pacity. After these two studies, the interest
in exercise training in CHF has greatly in-
creased during this decade. The total number
of the patients who have participated in the
studies is approaching 1000. The main stud-
ies on exercise training with CHF patients
are listed in Table 1.
2.3.2.Methods
The inclusion criteria in the various studies
have been quite strict but very similar. The
NYHA functional class of the patients has
been II-III with left ventricular ejection frac-
tion below 40%, and the patients have been
haemodynamically stable for at least 3
months. The aetiology has, in the majority
of cases, been classified as either ischaemic
or dilated cardiomyopathy, but patients with
exercise restricting ischaemia have usually
been excluded. Patients with CHF due to
valvular heart disease have not generally
been included.
Dynamic training has been used in the
majority of the studies (Sullivan et al. 1988a,
Coats et al. 1992, Kavanagh et al. 1996,
Keteyian et al. 1996). Concerned about over-
straining the heart, some groups have pre-
ferred local muscle training (Koch et al.
1992, Gordon et al. 1996). The intensity of
the training in most of the studies has been
moderate (50-60% of the peak VO2, 60-80%
of the maximal heart rate, 60-80% of the
maximal work load). In low-intensity train-
ing, the work load has corresponded to less
than 50% of the peak VO2 (Belardinelli et
al. 1995, Demopoulos et al. 1997). High-
intensity training has used working loads
exceeding 70% of the peak VO2 (Sullivan et
al. 1988a, Hambrecht et al. 1995). The
weekly exercise time has been between 1.5
and 6.5 hours. The most common training
period has been 8-12 weeks, but it has var-
ied from 3 weeks to 14 months.
2.3.3. Results
According to the published data, CHF pa-
tients can succesfully participate in physi-
cal training. In some cases, training has been
stopped due to worsening of heart failure,
but in controlled studies, the training group
has not differed from the controls in this
respect (Coats et al. 1992, Hambrecht et al.
1995, Kavanagh et al. 1996, Keteyian et al.
1996). In one study, there was a strong trend
that patients with ischaemic cardiomyopa-
thy, lower left ventricular ejection fraction
or higher age were more prone to drop out
more frequently than those with dilated car-
diomyopathy, better ejection fraction or low-
er age (Keteyian et al. 1996).
2.3.3.1.  Haemodynamics and
ventilation
Training has had no effect on central circu-
lation, left ventricular dimensions or ejec-
tion fraction at rest or during exercise (Sul-
livan et al. 1988a, Hambrecht et al. 1995).
.
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However, cardiac output has been shown to
increase at maximal work load (Coats et al.
1992, Hambrecht et al. 1995) and at sub-
maximal exercise levels, it has remained
unaltered (Sullivan et al. 1988a, Hambre-
cht et al. 1995) or increased (Coats et al.
1992). Leg blood flow has been higher at
peak exercise after training associated with
a decrease in leg vascular resistance (Sulli-
van et al. 1988a, Hambrecht et al. 1995).
Physical training has been shown to reduce
VE and VE/VCO2 during exercise (Davey et
al. 1992, Sullivan et al. 1989b) and it has also
retarded the rise of VCO2/VO2, referring to
improved aerobic capacity (Sullivan et al.
1989b).
2.3.3.2. Exercise capacity
Physical training has
 
improved peak VO2 by
5-33% (Sullivan et al. 1988a, Coats et al.
1992, Davey et al. 1992, Belardinelli et al.
1995, Hambrecht et al. 1995, Kavanagh et
al. 1996, Keteyian et al. 1996, Meyer et al.
1996, Demopoulos et al. 1997, Willenheim-
er et al. 1998). In one study, the exercise time
at a constant submaximal work load increased
by 52% (Sullivan et al. 1989b). Few studies
have reported on subgroups that have not
gained benefit from training. Scalvini et al.
(1992) observed that peak VO2 did not im-
prove if it was below 15 ml/kg/min before
training. Wilson et al. (1996) found that only
1 out of 11 patients with a more reduced car-
diac output response to exercise at baseline
responded to training, while the number was
9 out of 21 in those with a better cardiac out-
put response to exercise (mean cardiac out-
put at peak exercise 7.3±1.3 l/min and
10.3±2.1 l/min, respectively).
2.3.3.3. Neurohormonal activation and hor-
monal status
Physical training has reduced plasma no-
radrenaline level and noradrenaline spillo-
ver at rest (Hambrecht et al. 1995, Europe-
an Heart Failure Trial Group 1998, Coats et
al. 1992) and plasma noradrenaline level
during submaximal exercise (Hambrecht et
al. 1995). The attenuation of the sympathetic
and increase in the parasympathetic activi-
ty has also been suggested by an increase in
HRV (Adamopoulos et al. 1995). Recently,
one group reported a decrease in the resting
level of plasma ANP, aldosterone and angi-
otensin II after a 4-month period of endur-
ance training (Braith et al. 1999). However,
in another study, the resting level of plasma
ANP or aldosterone did not change (Euro-
pean Heart Failure Trial Group 1998). The
influence of physical training on anabolic
and catabolic hormones and thus on ana-
bolic / catabolic balance has been poorly
evaluated.
2.3.3.4. Skeletal muscle
Physical training increases the strength of
skeletal muscles in patients with CHF. This
has been shown by high-intensity strength
training of separate muscle groups in which
strength has increased by 40% (Magnusson
et al. 1996).
Physical training seems to improve me-
tabolism in skeletal muscle. Nuclear mag-
netic resonance spectroscopy studies have
shown that both local muscle training and
dynamic exercise training reduce phospho-
creatine depletion during exercise and en-
hance phosphocreatine resynthesis during
recovery (Minotti et al. 1990, Adamopou-
. .
..
.
.
.
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los et al. 1993). This is in accordance with
the finding that physical training increases
the volume density of mitochondria (Belar-
dinelli et al. 1995, Hambrecht et al. 1997).
Further, enzyme activities of citrate synthase
in the Krebs’ cycle and 3-hydroxyacyl-CoA-
dehydrogenase in fatty acid oxidation have
been reported to increase (Magnusson et al.
1996, Gordon et al. 1996). Mean area of
both slow-twitch and fast-twitch fibres has
been found to increase (Belardinelli et al.
1995), and in one study, the percentage dis-
tribution of muscle fibres was shown to shift
towards a greater proportion of aerobic
slow-twitch fibres (Hambrecht et al. 1997)
although this has not been confirmed by oth-
ers (Belardinelli et al. 1995, Magnusson et
al. 1996).
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3. HYPOTHESES OF THE STUDY
Dynamic physical training
1. improves exercise capacity and alleviates symptoms
2. reduces the increased ventilatory response during exercise
3. reverses the autonomic dysfunction and the neurohormonal activation
4. does not affect the anabolic / catabolic  balance
5. improves the aerobic capacity to produce energy in skeletal muscle
in patients with stable mild-to-moderate CHF.
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4. SUBJECTS AND METHODS
4.1. Study population
Twenty-seven patients with CHF from the
out-patient clinics of Helsinki University
Central Hospital, Malmi Hospital in Helsin-
ki and Jorvi Hospital in Espoo volunteered
for this study during 1991-1994. They were
under 65 years of age (range 25-64 years),
and all but one were men. Their history of
CHF was longer than 6 months, and the clin-
ical condition of the patients had been sta-
ble for at least 3 months prior to the study.
The NYHA functional classes were II - III.
The diagnosis was based on symptoms, i.e.
exercise limiting dyspnea and/or muscle
fatigue, and a decreased level of the left ven-
tricular ejection fraction below 40%, which
was determined by echocardiography. The
aetiology of CHF was dilated cardiomyop-
athy (n=18) or ischaemic heart disease
(n=9). All patients with ischaemic aetiolo-
gy had had a myocardial infarction but had
neither exercise-induced chest pain nor
electrocardiographic evidence of exercise
ischaemia. The patients with a pulmonary
disease or diabetes were excluded. The pa-
tients had to have their permanent residence
within 50 kilometers of Helsinki Universi-
ty Central Hospital.
The medication of the patients had been
optimized and had been constant for at least
one month before they entered the study. Out
’
of the 27 patients, 25 used an ACE-inhibi-
tor (mean dose of enalapril 13 mg/d or of
captopril 48 mg/d), 24 were on digitalis, 22
on diuretics (mean dose of frusemide 99 mg/
d) and 6 received β-blockers. As far as pos-
sible, the doses were kept constant during
the study. The diuretic dose was allowed to
be changed if necessary.
The patients gave an oral informed con-
sent for this study, which was approved by
the Ethics Committee of the First Depart-
ment of Medicine of Helsinki University
Central Hospital.
The patients were randomized either to a
training or a control group. The training
group comprised 12 patients and the con-
trol group 15.
4.2. Training
The training programme consisted of two
successive 3-month periods. In the first pe-
riod, ergometer cycling was performed three
times a week under the supervision of a
physician. Each session lasted for 30 min.
During the first 4 minutes of each training
session, the work load was gradually in-
creased to the training level, and each ses-
sion ended with a 2-minute period at a light
work load of 25-50W. For the first 2-3
weeks, the training level was settled to cor-
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respond to 50-60% of the peak VO2 at base-
line. Afterwards, the heart rate was kept at
the same level with ECG-monitoring, and
the load was adjusted accordingly. In the
latter 3-month period, training was per-
formed at home with the same training fre-
quency and was composed mainly of walk-
ing and cycling, but also of rowing and
swimming. The patients were advised to
keep the same training intensity as in the
supervised training on the basis of perceived
exertion. No diary registering compliance
was kept, but this was estimated by inter-
views. The control patients were advised not
to change their previous physical activities
during the 6-month period.
4.3. Test performance
The patients were hospitalized for three days
at baseline, after 3 and after 6 months for
performing the tests.
4.3.1. Haemodynamic measurements
Central haemodynamic parameters were
measured at rest in supine position. A triple
lumen Swan Ganz balloon catheter was in-
serted percutaneously via the right internal
jugular vein for right heart catheterization.
The right atrial, right ventricular, pulmonary
arterial and pulmonary capillary wedge
pressures were recorded. Cardiac output was
determined by the thermodilution method
and cardiac index by dividing cardiac out-
put by the body surface area (Study I). The
catheterization was performed only at base-
line and after 3 months. A third catheteriza-
tion was regarded as unnecessary because
no changes in central haemodynamics ap-
peared during the more intensive supervised
training period.
The dimensions of cardiac chambers and
left ventricular ejection fraction were deter-
mined by 2-dimensional and M-mode trans-
thoracic echocardiography (Toshiba SSH-
160A), and the cardiothoracic ratio was
measured from the chest X-ray (Study I).
Heart rate and brachial blood pressure
were determined after a 30-minute rest pe-
riod in supine position at 9 a.m. before the
intake of the morning meal and medication.
Blood pressure was measured by a
sphygmomanometer.
4.3.2.Exercise capacity and
ventilatory function
Two exercise test protocols on an upright
bicycle ergometer were used, a graded max-
imal exercise test with respiratory gas anal-
ysis and an exercise endurance test at a con-
stant submaximal work load corresponding
to 85% of the baseline peak VO2 (Study I).
The interval between the tests was 2 days.
In performing the graded maximal exer-
cise tests, the patients used an electrically
braked bicycle ergometer (Bosch ERG 220,
Robert Bosch GmbH, Berlin, Germany).
The test took place at 9 a.m. before their
intake of the morning meal and medication.
Each patient underwent a familiarization test
two days prior to baseline testing. The test
was started with a workload of 10 Watts (W)
and proceeded with increments of 20 W
every 2 minutes up to the symptom-limited
maximum, which was indicated by reach-
ing the rate 19-20/20 in the Borg scale of
perceived exertion (Borg 1962) and exceed-
ing the VCO2/VO2 level of 1.00. Continu-
ous analysis of expired gases, starting at rest
.
.
. .
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when the patients were sitting on the bicy-
cle, was carried out, and the ventilatory var-
iables were calculated at 30-sec intervals
using microcomputer-assisted equipment
(EOS Sprint gas exchange analysis system,
Erich Jaeger GmbH, Würzburg, Germany).
Respiratory gases were collected using a
tightly attached face mask (Rudolph series
7910, Hans Rudolph Inc.,Wyandott, Kan-
sas City, MO, U.S.A.). The mixed expirato-
ry gas was sampled for analysis from a bag
of 10 liters. The equipment consisted of an
infra-red absorption analyser for carbon
dioxide and a paramagnetic analyser for ox-
ygen. Ventilatory variables measured were
the following: minute ventilation (VE; l/min),
breathing frequency (1/min), tidal volume (l),
oxygen consumption (VO2; l/min), carbon
dioxide production (VCO2; l/min), oxygen
pulse (VO2/HR; ml), respiratory exchange
ratio (VCO2/VO2), ventilatory equivalent for
carbon dioxide (VE/VCO2), ventilatory
equivalent for oxygen (VE/VO2) and end-tid-
al carbon dioxide fraction (FetCO2; %). ECG
and heart rate were monitored continuously,
and blood pressure was measured at each
work load with a sphygmomanometer.
Exercise endurance was determined by
the duration of ergometer cycling at a con-
stant submaximal work load corresponding
to 85% of the peak VO2 at baseline. The test
was performed at 2 p.m. The patients took
their normal medication in the morning, and
they had a light lunch at the ward three hours
before the test. The test was started with a
warm-up of 4 minutes: the first 2 minutes
were cycled at one-third and the next 2 min-
utes at two-thirds of the final workload. The
warm-up period was included in the total
cycling time. The first four patients in the
control group did not perform this test be-
cause it did not belong to the protocol when
they entered the study.
4.3.3. Blood samples
The samples for determination of the basal
levels of plasma adrenaline, noradrenaline,
cyclic adenosine monophosphate (cAMP),
N-terminal pro atrial natriuretic peptide (Nt-
proANP) and serum cortisol, growth hor-
mone, insulin and free fatty acids (FFA) and
venous blood lactate were taken after over-
night fasting at 9 a.m. after a rest of 30 min-
utes in supine position before the graded
maximal exercise test (Study III). A needle
had been inserted into a cubital vein 30 min
before sampling. The corresponding sam-
ples were taken immediately after the exer-
cise test stopped when the patient was still
sitting on the bicycle (Study III). In addi-
tion, samples for venous blood lactate were
taken every two minutes at the end of each
work load. The anaerobic threshold was
determined graphically from an abrupt in-
crease in lactate concentration using the log-
log transformation method (Beaver et al.
1985) (Study I).
 Samples for serum cortisol, growth hor-
mone, insulin and FFA, plasma adrenaline
and noradrenaline and venous blood lactate
determinations were also taken in connec-
tion with the exercise endurance test with
constant submaximal workload (Study III).
The levels of serum cortisol, growth hor-
mone, insulin and FFA and venous blood
lactate were determined before the test on
the bike, immediately after the cycling,
while the patient was still sitting on the bi-
cycle and, in addition, if the exercise time
was longer at 3 and 6 months, at the time
point equal to the duration of cycling at base-
line. Plasma adrenaline and noradrenaline
were determined at the end of the test at
baseline and at the corresponding time point
after 3 and 6 months or, if the exercise time
.
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was then shorter, at the end of test.
 The samples for serum testosterone, sex
hormone binding globulin (SHBG) and de-
hydroepiandrosterone sulfate (DHEAS)
were taken after overnight fasting at rest in
the morning. Serum free testosterone level
was calculated on the basis of serum testo-
sterone and SHBG values according to An-
dersson (1976).
4.3.3.1. Laboratory determinations
Plasma from blood samples for plasma
adrenaline and noradrenaline (Tris-EGTA-
DTT -plasma: Trizma base 0.5 mol/l, eth-
yleneglycol-bis-N,N-tetra acetic acid 0.25
mol/l, dithiothreitol 0.25 mol/l) was sepa-
rated and stored at -70 °C until assay. The
plasma concentrations were determined by
high-performance liquid chromatography
using the method described by Scheinin et
al. (1991).
Blood samples for plasma Nt-proANP
and cAMP and serum cortisol, growth hor-
mone, insulin, FFA, testosterone, SHBG,
DHEAS and albumin were collected on ice
and centrifuged at 4 °C. They were stored
at -20 °C until analysis. Plasma Nt-proANP
(Biotop, Oulu, Finland), cAMP (Amersham
International Inc., Amersham, UK) and se-
rum cortisol (Orion Diagnostica, Espoo,
Finland), growth hormone (CIS bio inter-
national, Gif-sur-Yvette, France), insulin
(Kabi Pharmacia Diagnostics AB, Uppsa-
la, Sweden), testosterone (Orion Corpora-
tion Farmos, Turku, Finland) and DHEAS
(Diagnostic Products Corporation, Los An-
geles, CA, U.S.A) were determined by ra-
dioimmunoassay. Serum FFA was deter-
mined fluorometrically by an enzymatic
method (Shimizu et al. 1979) and serum
SHBG fluoroimmunometrically (Wallac
Oy, Turku, Finland). Serum albumin was de-
termined by the bromcresol purple method
(Pinnell et al. 1978) and blood lactate by an
enzymatic method from EDTA blood, which
was frozen on dry-ice immediately after
sampling.
4.3.4. Heart rate variability
HRV was determined from a 20-hour am-
bulatory ECG recording at baseline and af-
ter 3 months in patients who were in sinus
rhythm (8 patients in the training group and
12 in the control) (Study II). The recording
was made during a day, which included no
exercise tests. It began at 12 a.m. and ended
at 8 a.m. the next morning. The patients were
encouraged to avoid bed rest while awake.
A two-channel recorder (Marquette 8500,
Marquette Electronics Inc., Milwaukee, WI,
USA) was used. The tapes were analysed
using a Marquette 8000 Holter Analysis
System (version 5.8 software), which pro-
vides R wave detection and QRS complex
classification. The classification was over-
read and corrected when necessary. Only
normal sinus beat intervals were used for
calculation of HRV. Each interval to be ex-
cluded, due to ectopy or artifact, was re-
placed by holding the previous coupling
interval level through to the next valid cou-
pling interval. Fast Fourier transformation
was used to process the beat-to-beat fluctu-
ations to frequency. The spectral bands used
were high frequency 0.15-0.40 Hz (HF), low
frequency 0.04-0.15 Hz (LF), and very low
frequency 0.008-0.04 Hz (VLF). The spec-
tral measures computed as amplitudes,
which are square roots of areas under the
power spectrum, are presented in ms.
The HF and LF components and the LF/
HF ratio were determined for each hour. The
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graphs were compared both as a whole and
divided into day (12 a.m. - 10 p.m.) and night
(10 p.m. - 8 a.m.) periods. In addition, the
HF, LF and VLF components and the LF/
HF and VLF/HF ratios were determined
during two daytime periods, one sedentary
and one active. These 30-minute periods
were selected on the basis of the heart rate
trend curve. The sedentary period was de-
termined as a stable low heart rate level be-
low the daytime average and the active pe-
riod as a stable high heart rate level above
it.
4.3.5. Skeletal muscle
A skeletal muscle biopsy was taken at rest
on a non-exercise day (Study IV). A Berg-
ström needle using suction was employed
to sample the lateral portion of the right
quadriceps femoris muscle. After local an-
aesthesia of the skin, a small incision was
made with a scalpel and the biopsy needle
was advanced 3-4 cm into the muscle at the
mid-area between the greater trochanter and
the knee. The subsequent biopsies at 3 and
6 months were taken 5 cm apart from the
previous ones to avoid the earlier biopsied
muscle area. The samples were immediate-
ly frozen in liquid nitrogen and stored at
-70°C until analysed.
4.3.5.1. Fiber distribution, size and capil-
lary density.
Serial 10 µm transverse sections were cut
in a cryostat at -20°C and mounted on cov-
er glasses. Muscle fibre types were identi-
fied by staining for myosin ATPase activity
after preincubation at pH 4.35 when slow-
twitch fibres are stained dark and fast-twitch
fibres light. The number of muscle fibres of
the two types was counted, and the percent-
age distribution calculated. The muscle fi-
bre size was determined with a computer-
ized digitalizing programme by drawing
along the edges of the fibres. The capillar-
ies were stained immunohistochemically
(Vectastain Elite ABC kit, Vector Labora-
tories, Burlingame, CA, U.S.A.). The
number of capillaries adjacent to each mus-
cle fibre was counted from the microscope’s
monitor screen.
4.3.5.2. Enzyme activities.
For the determination of enzyme activities,
the muscle samples were homogenized in
10 volumes of ice-cold 50 mmol/l Tris-HCl
buffer, pH 7.4, containing 0.5 mmol/l dithi-
othreitol (DTT), 2 mmol/l MgCl2 and 1
mmol/l EDTA. Protein content of the wa-
ter-diluted homogenates was measured ac-
cording to Lowry et al. (1953). The kinetics
of the reactions were followed in a Transcon
102 FN fluoronephelometer (Elomit Ltd,
Helsinki, Finland).
Phosphorylase (PHRL) and active phos-
phorylase (PHRLa). The activity was meas-
ured by a modification of a method by
Härkönen et al. (1982). The assay medium
for PHRL contained 50 mmol/l Imidazole-
HCl buffer, pH 7.0, 0.5 mmol/l MgCl2, 20
mmol/l K2HPO4, 0.1 mmol/l EDTA, 0.5
mmol/l DDT, 0.1 mmol/l NADP+, 5 mmol/
l glycogen (as glycosyl units), 0.02% bo-
vine serum albumin (BSA), 1 mmol/l 5-
AMP, 600 mU/ml phosphoglucomutase and
280 mU/ml glucose-6-phosphate dehydro-
genase. For PHRLa, the assay medium did
not contain 5-AMP. The increase of NADPH
fluoresence was followed at +25°C. In cal-
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culations, 5 µmol/l of glucose-6-phosphate
was used as calibrator.
Phosphofructokinase (PFK). Assay me-
dium was principally the same as described
by Lowry et al. (1978) and contained 50
mmol/l Tris-HCl, pH 7.4, 1 mmol/l ATP, 2
mmol/l MgCl2, 0.02% BSA, 10 mmol/l
K2HPO4, 1 mmol/l AMP, 1 mmol/l DTT, 10
µmol/l NADH, 50 U/ml triosephosphate iso-
merase, 90 mU/ml aldolase and 1 U/l glyc-
erin-3-phosphate dehydrogenase. The reac-
tion was initiated by adding 2 mmol/l of
fructose-6-phosphate, and the disappearance
of NADH was followed kinetically at +25°C
for 1-2 minutes.
α-ketoglutarate dehydrogenase (α-
KGDH). Assay medium contained 100
mmol/l Tris-HCl, pH 7.4, 2 mmol/l DTT, 1
mmol/l KCN, 0.4 mmol/l ADP, 1 mmol/l
NAD+ and 0.5 mmol/l CoA (Read et al.
1977). The reaction was started by adding
1 mmol/l of α-ketoglutarate. Formation of
NADH was followed kinetically at +25°C
for 2-3 minutes. In calculations, 5 µmol/l
of NADH in final concentration in the as-
say medium was used as calibrator.
Carnitine palmitoyltransferase I (CPT I).
The release of CoA in the reaction with
palmitoyl-CoA and carnitine was used as
an index of enzyme activity. The assay me-
dium contained 100 mmol/l Tris-HCl, pH
7.4, 80 mmol/l KCl, 1 mmol/l KCN, 1
mmol/l EDTA, 0.1% BSA, 1 mmol/l α-ke-
toglutarate, 0.5 mmol/l NAD+, 1 mmol/l
carnitine and 50 mU/ml α-KGDH. The re-
action was started by adding 50 µmol/l of
palmitoyl-CoA and followed kinetically at
+25°C for 2-3 min. In calculations, 5 µmol/
l of NADH was used as calibrator.
Carnitine palmitoyltransferase II (CPT
II). Formation of carnitine in the reaction
between palmitoyl-carnitine and CoA was
used as an index of enzyme activity. The
method of Deufel and Wieland (1983) was
used with the following modifications: Car-
nitine formed in the reaction was measured
using carnitine acetyltransferase (CAT).
CoA formed in this reaction from acetyl-
CoA was measured in the medium contain-
ing 50 mmol/l Imidazole-HCl buffer, pH
6.7, 1 mmol/l MgCl2, 0.5 mmol/l EDTA, 0.5
mmol/l NAD+, 0.5 mmol/l α-ketoglutarate,
1 mmol/l DTT, 0.02% BSA and 0.1 mmol/
l acetyl-CoA and 40 mU/ml of α-KGDH.
Both 400 µl of this solution and 20 µl of
medium containing CoA were pipetted to
Transcon microcuvettes, initial fluorescence
was read and the reaction initiated by add-
ing 20 mU of CAT. The reaction was com-
pleted at +25°C in 5 minutes, and forma-
tion of carnitine was calculated. Carnitine
in concentration of 5 µmol/l was used as
calibrator.
4.3.5.3. Strength and electrophysiology
Two test protocols were performed by 21
patients (8 and 13 in the training and con-
trol groups, respectively) to assess strength
and strength endurance of the knee exten-
sors (Study IV).  The patients were seated
in a special chair to standardize the limb
position to a 90-degree flexion of the knee
and to immobilize the trunk. A force trans-
ducer was placed on the fore-edge of the
lowest third of the leg, and the force was
recorded with a dynamometer (Kyowa Elec-
tronic Instruments Co, Tokyo, Japan). The
equipment was not in our use until the first
6 patients had entered the study.
In the first test, the patients performed two
3-second maximal voluntary contractions of
the right quadriceps femoris muscle sepa-
rated by one minute of rest. The maximal
voluntary force and the time in which 90%
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of the force was achieved were determined.
In the second test, after a 4-minute rest
period, the patients maintained a maximal
voluntary contraction for 40 seconds. The
total force, its mean and the slope demon-
strating the decrease of the force, i.e.
strength endurance were determined. A two-
channel surface EMG was registered using
electrode pairs with a distance of 30 mm
and situated parallel to vastus lateralis mus-
cle fibres. The EMG signals were amplified
by EMG equipment (Dantec, Skovlunde,
Denmark), sampled digitally and analysed
off-line to calculate the muscle-fibre con-
duction velocity and velocity slope.
Macro-EMG amplitude and area were
determined during slight voluntary contrac-
tion of the right quadriceps femoris muscle
in supine position.
4.3.6. Statistical analysis
The statistical analysis of this thesis was
performed by making the comparisons only
between the groups. In those parameters
which were assessed at the baseline, at 3
months and at 6 months, the analysis of var-
iance with repeated measures was used to
test changes between the groups during the
study. When a significant change was de-
tected, Fisher’s protected least significant
difference was used to isolate it. The analy-
sis of variance with repeated measures was
also used to test the changes in the 20-hour
HRV graphs between the groups. However,
the Mann Whitney U test was used for the
HRV data on the daytime sedentary and ac-
tive periods. The Mann Whitney U test was
also used to compare the groups at baseline.
In Study I, the Mann Whitney U test was
originally used to compare the changes be-
tween the two groups. After a later recom-
mendation of the referees, the analysis of
variance with repeated measures has been
used in this thesis for the analysis of the data
in Study I.
The hormonal responses in single exer-
cise tests, i.e. the difference between post-
exercise and basal levels, were analysed by
the Wilcoxon signed rank test .
In the graded maximal exercise test, sub-
maximal exercise data of the ventilatory
parameters and heart rates at 30, 50, 70 and
90 W were combined, and the analysis was
performed by an area-under-the-curve tech-
nique (Study I).
The level of significance was set at p <
0.05. The data are given as mean ± SEM
unless otherwise stated. The statistical anal-
yses were carried out with Statview 512 sta-
tistical programme (Abacus Concepts, Inc.,
Berkeley, CA, U.S.A.) for the Macintosh
computer (Apple Inc., Cupertino, CA,
U.S.A.).
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5. RESULTS
5.1. Baseline characteristics of the subjects
The groups did not differ in clinical characteristics at baseline (Table 2).
______________________________________________________________________________
Control group Training group
______________________________________________________________________________
Patients (male+female; n) 15 (14+1) 12 (12+0)
Aetiology of heart failure
Dilated cardiomyopathy (n) 10 8
Ischemic cardiomyopathy (n) 5 4
Medication
Digoxin (n) 12 12
Diuretic (n) 11 11
ACE inhibitor (n) 14 11
Long acting nitrate (n) 2 4
Beta blocking agent (n) 2 4
Age (years) 52±9 52±7
Time from CHF diagnosis (years) 2.8±3.0 4.8±4.9
NYHA functional class 2.3±0.7 2.4±0.5
Peak VO2 (ml/kg/min) 18.3±5.0 19.3±5.5
LV EF (%) 25±7 24±5
______________________________________________________________________________
ACE=angiotensin converting enzyme, CHF=chronic congestive heart failure, NYHA=New York
Heart Association, VO2=oxygen consumption, LV EF=left ventricular ejection fraction.
The data of the upper section are presented as number of patients, the lower section as mean ± SD.
.
.
Table 2 -Clinical characteristics of the patients
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5.2. Medication
The baseline medication is shown in Table
2. The diuretic dose was raised in three pa-
tients in the control group during the study.
The dose was lowered in one patient in both
groups. The ACE-inhibitor dose had to be
lowered in one patient in both groups dur-
ing the first month because of symptomatic
hypotension.
5.3. Compliance
The individual attendance at the supervised
training sessions varied from 85 to 100%:
one individual session was interrupted by
the supervisor because of an abundance of
ventricular premature beats, and some had
to be cancelled because of acute infections.
No diary was kept during the home training
period, and thus the intensity and frequen-
cy of exercise could not be exactly defined.
However, estimated on the basis of patient
interviews, the intensity did not reach the
level of the supervised training. There were
no drop-outs in either group during the
study. One patient in the control group was
hospitalized 1.5 months after the study be-
gan because of fluid retention, but he com-
pleted the study according to the protocol.
He remained in NYHA functional class III,
but his peak VO2 improved from 10.4 ml/
kg/min at baseline to 13.9 ml/kg/min at 3
months. These results were included in the
analyses. However, his hormone and skele-
tal muscle data were excluded.
5.4. Haemodynamic
measurements (Study I)
Heart rate, blood pressure, right atrial, right
ventricular, pulmonary arterial and pulmo-
nary capillary wedge pressure or cardiac
index did not change at rest between the
groups. Left ventricular end diastolic diam-
eter and ejection fraction also remained un-
changed (Table 3).
.
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5.5. Exercise capacity and
NYHA functional class
(Study I)
Exercise capacity and NYHA class data are
presented in Figure 2. The groups did not
differ in this respect at baseline. Two pa-
tients in the control group and three in the
training had their peak VO2 below 14 ml/
kg/min, eight and five patients between 14
and 20 ml/kg/min, and five and four patients
above 20 ml/kg/min, respectively.
_____________________________________________________________________
 Control group                                         Training group
                                    ________________________     ________________________
0 mo 3 mo 6 mo 0 mo 3 mo 6 mo
_____________________________________________________________________
HR (beats/min) 69±3 66±2 65±3 76±4 74±3 77±5
RR systolic (mmHg) 108±4 111±4 112±3 116±4 112±3 117±3
diastolic (mmHg) 70±3 74±2 75±3 76±3 76±2 78±2
Cardiothoracic ratio 0.50±0.02 0.50±0.02 0.51±0.02 0.50±0.02 0.49±0.02 0.50±0.02
RAP mean (mmHg) 6±1 5±1 6±1 7±2
PAP systolic (mmHg) 37±5 33±4 37±4 31±3
diastolic (mmHg) 18±3 16±2 19±3 15±2
PCWP mean (mmHg) 16±3 13±2 15±3 13±2
Cardiac index (l/min/m2) 2.3±0.1 2.3±0.1 2.4±0.1 2.5±0.2
LV EF (%) 25±2 26±2 26±1 24±2 21±1 25±3
_____________________________________________________________________
mo=months, HR=heart rate, RR=blood pressure, RAP=right atrial pressure, PAP=pulmonary artery
pressure, PCWP=pulmonary capillary wedge pressure, LV EF=left ventricular ejection fraction.
The data are given as mean ± SEM. Right heart catheterization was performed only at baseline and
at 3 months.
Table 3 -Haemodynamic parameters at rest at baseline and after 3 and 6 months
The peak VO2 improved in the training
group compared with the controls
 
(p<0.05
at both 3 and 6 months). It was 19.3±1.6
ml/kg/min at baseline and 21.7±2.3 ml/kg/
min after supervised training. This level was
preserved during home-based training. Nine
patients in the training group improved their
peak VO2, it decreased in two patients and
remained unchanged in one. The maximal
work load increased from 118±10 W at base-
line to 140±13 W at 3 months and to 137±12
W at 6 months. The increase was signifi-
.
.
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Figure 2.
Peak oxygen consumption (peak VO2), anaerobic threshold, exercise duration at constant
submaximal work load (corresponds to 85% of the peak oxygen consumption at baseline),
and New York Heart Association functional class at baseline, after 3 and 6 months. The
control group in open bars and the training group in grey bars. Anaerobic threshold was
determined as the level of oxygen consumption. # = p < 0.05 and ## p < 0.01 for difference
between the changes from baseline in the training vs the control group. The data are given
as mean ± SEM.
.
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cant compared with the change in the con-
trol group (p<0.01). There was also an im-
provement in anaerobic threshold compared
with the controls (p<0.05 at 3 months,
p<0.01 at 6 months).
Training did not affect the heart rate at
the submaximal work loads of the graded
maximal exercise test compared with the
control group but the peak heart rate rose
significantly (159±8 at baseline, 165±6 at 3
months and 166±6 at 6 months) (p<0.01 vs
controls). This increase was due to a corre-
sponding increase in the total heart rate re-
sponse, i.e. peak heart rate - heart rate be-
fore cycling, during the graded maximal
exercise test (p<0.01 at 3 and p<0.05 at  6
months vs controls).
The improvement in exercise endurance
at constant submaximal work load was sig-
nificant compared with the change in the
control group (p<0.01). Every patient in the
training group improved his result. At 3
months, the mean improvement was 88%
(range 49-201%) and at 6 months 84%
(range 24-199%). The corresponding chang-
es in the control group were 14% (range
-26 - +70%) at 3 months and 19% (range
-35 - +50%) at 6 months.
NYHA functional class improved by one
class in 6 patients in the training group dur-
ing the first three months. During the home-
training period, one patient improved by one
class and one patient, who had improved
during the supervised training period, dete-
riorated by one class. In the control group,
a deterioration by one class was observed
in one patient during the latter 3-month pe-
riod. The difference between the changes
of the groups was significant (p<0.01). The
change in NYHA functional class correlat-
ed with the change in peak VO2 (r2=0.40,
p<0.01) in the training group but not with
the change in exercise endurance at constant
submaximal work load (r2=0.13, p=0.08).
The weight of the patients did not change
in either group. The weights were 79.8±2.9
kg at baseline, 79.6±2.9 kg at 3 months and
79.4±2.9 kg in the training group and
80.0±3.1 kg, 79.2±2.8 kg and 78.9± 3.0 kg
in the controls, respectively.
5.6. Ventilatory function
during exercise
(Study I)
VE decreased at the submaximal work loads
from 41.1±5.5 l/min at baseline to 34.6±4.9
l/min at 3 months and to 35.5±4.6 l/min at 6
months in the training group (Fig. 3). The
decrease was significant compared with the
change in the control group at 6 months
(p<0.05; p=0.06 at 3 months). At peak ex-
ercise, the changes in VE did not differ be-
tween the groups.
Training lowered VE/VCO2 at the sub-
maximal work loads (p<0.01 vs control
group), but not at peak exercise. VE/VO2
decreased also at the submaximal work
loads (p<0.05 vs controls) but not at peak
exercise. Training increased FetCO2 at sub-
maximal workloads during the first 3
months (p<0.01 vs controls) but there was
no difference between the changes after 6
months (Fig. 3).
Training decreased VCO2/VO2 at the sub-
maximal work loads during the supervised
period from 0.93±0.02 to 0.86±0.01 (p<0.05
vs control group), in the control group
0.92±0.01 and 0.88±0.01, respectively (Fig.
3). The changes did not differ after 6 months.
. .
. .
. .
.
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Figure 3.
The graphs of minute ventilation, ventilatory equivalent for carbon dioxide (VE/VCO2),
end-tidal carbon dioxide fraction (FetCO2) and respiratory exchange ratio (VCO2/VO2)
during graded maximal exercise test. The control group is in the left panel and the training
group in the right; (                   ) baseline, (                  ) after 3 and (                  ) after 6 months.
# = p<0.05 and ## = p<0.01 for difference between the changes from baseline in the
training vs the control group. The data are given as mean ± SEM.
. .
. .
40
5.7. Hormones at rest and the
response during exercise
(Study III)
The plasma noradrenaline level was
2.53±0.34 nmol/l at rest at baseline in the
training group, 2.51±0.31 nmol/l after 3
months and 2.05±0.26 nmol/l after 6 months
(Fig. 4). This change, as well as the change
in the plasma cAMP level at rest, did not
differ from those of the control group. Train-
ing did not affect the plasma levels of adren-
aline and ANP at rest, either (Fig. 4; Study
III, page 459, Fig. 1).
The levels of serum cortisol and insulin
at rest were unaffected by training (Fig. 4),
nor was there any intergroup difference in
the change in serum growth hormone (Study
III, page 459, Fig. 1). The levels of serum
free testosterone and DHEAS were normal-
ly age-related in both groups at baseline.
They did not increase or decrease during the
study period (Table 4). The free testoster-
one / cortisol -ratio was lower in the control
group at baseline (p<0.01). The change in
this ratio did not differ between the groups
during the study. No change occurred in the
DHEAS / cortisol -ratio, either (Table 4).
At baseline, plasma catecholamine levels
increased significantly in the graded maxi-
mal exercise test in both study groups
(p<0.01 basal vs post exercise) (Fig. 4;
Study III, page 459, Fig. 1). The plasma
noradrenaline response further increased in
the training group at 3 months (p<0.05 vs
control group) (Fig. 4). Plasma cAMP re-
sponse remained similar. During the exer-
cise test with constant submaximal work
load, the change in the levels of plasma
adrenaline and noradrenaline after 3 and 6
months at the time point equal to the dura-
tion of cycling at baseline, did not differ
between the groups.
The rise in serum cortisol and growth
hormone levels during the graded maximal
exercise test was significant in both groups
at baseline (Fig. 4; Study III, page 459, Fig.
1). Training did not have an effect on these
responses in comparison with the control
patients nor did the changes in the cortisol
response to the exercise test with constant
submaximal work load differ between the
groups during the study (Study III, page 461,
Fig. 2) .
Serum insulin did not change significantly
in either group during the graded maximal
exercise at baseline. There was no differ-
ence in serum FFA response, either. Train-
ing did not change the response of serum
insulin and FFA to exercise (Fig.4; Study
III, page 459, Fig. 1 and page 461, Fig. 2).
5.8. Heart rate variability
(Study II)
The groups differed in some parameters at
baseline. The HF component was lower and
the LF/HF ratio higher in the training group
in the 20-hour recording. The HF compo-
nent was also lower during the selected ac-
tive daytime period.
The HF component increased in the train-
ing group during the supervised training
(p<0.05 vs control group) (Fig. 5; Study II,
page 492, Figs. 1 and 2). The difference in
the change between the groups was more
marked at night (p<0.01). On the other hand,
the LF/HF ratio was decreased by training
(p<0.01 vs controls), primarily because of
the decrease in the daytime (p<0.01 vs con-
trols) (Fig. 5; Study II, page 493, Figs. 3
and 4). The change in the LF component
did not differ between the groups.
The changes in HRV components during
41
Figure 4.
The graphs of plasma noradrenaline, N-terminal pro atrial natriuretic peptide, serum cor-
tisol, and insulin after 30 min supine rest (basal) and immediately after stopping cycling
in graded maximal exercise test, the patient still sitting on the bicycle (post exercise). The
control group is in the left panel and the training group in the right. (               ) baseline,
(                ) after 3 and (                 ) after 6 months. # = p<0.05 for difference between the
changes of the response from baseline in the training vs the control group The data are
given as mean ± SEM. (From Figure 1 of Study III, page 459)
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daytime sedentary and active periods did not
differ between the groups, except the de-
crease in the VLF/HF ratio in the training
group during the active period (p<0.05 vs
controls) (Study II, page 494, Table 2).
5.9. Skeletal muscle (Study IV)
5.9.1. Fibre distribution, size and
capillary density
Because of technical reasons, the sections
of 2 patients in the control group were ex-
cluded from the analyses of fibre distribu-
tion, those of 6 and 3 patients in the control
and training groups, respectively from the
analyses of fibre area and those of 6 and 5
patients in the control and training groups,
respectively from the analyses of capillary
density.
Table 4 - The levels of anabolic steroid hormones
_______________________________________________________________________
              Control group    Trained group
0 mo 3 mo 6 mo 0 mo 3 mo 6 mo
_________________________________________________________________________________________________
Free testo, pmol/l 218±19 251±21 225±17 248±14 249±12 234±14
DHEAS, µmol/l 3.2±0.3 3.3±0.4 3.1±0.4 4.2±0.7 3.9±0.5 4.4±0.7
Free testo/cortisol x10-3 0.53±0.06 0.73±0.09 0.61±0.05 0.72±0.06# 0.76±0.05 0.74±0.04
DHEAS/cortisol 7.6±0.9 9.1±1.5 8.2±1.1 12.2±2.1 11.8±1.6 13.7±2.2
 _________________________________________________________________________________________________
mo=months, Free testo = free testosterone, DHEAS = dehydroepiandrosterone sulfate
# = p<0.01 between the groups at baseline
The data are presented as mean ± SEM
The percentage distribution of slow-
twitch and fast-twitch fibres and the mean
area of each fibre type did not change in
comparison between the groups. The capil-
lary density around both slow-twitch and
fast-twitch fibres remained also unchanged.
5.9.2. Enzyme activities
The enzyme activities could be determined
in all 12 patients in the training group and
in 13 patients in the controls. The changes
in the activities of both PHRL and PHRLa
did not differ between the groups during the
study period (Fig.6). The activity of PFK
increased in the training group compared
with the change in the control group
(p<0.05). After supervised training the mean
level of PFK activity was 52% higher than
the baseline value (Fig.6). Individually, 9
patients in the training group had higher
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Figure 5.
The mean amplitude of the high frequency component (upper panels) and the mean of the
low frequency/high frequency -ratio (lower panels) from the hourly data of ambulatory
recording in daytime (12 a.m. -10 p.m.) and at night (10 p.m. - 8 a.m.) registered at
baseline (0 months) and after 3 months. The control group is in the left panel (open bars)
and the training group in the right (grey bars). # = p<0.05 and ## = p<0.01 for difference
between the changes from baseline in the training vs the control group. The square brack-
et denotes the entire recording (= day+night). The data are given as mean±SEM. (From
Figures 1-4 of Study II, pages 492 and 493)
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PFK activity at both 3 and 6 months com-
pared with baseline. This was the case in 1
control patient. Training did not have an ef-
fect on the activity of α-KGDH (Fig.6).
Training did not change the activity of CPT
I when compared with the control group,
although the mean level was 44% and 64%
higher than the baseline value at 3 and 6
months, respectively in the training group.
In the control group, the figures were 15%
and 28%, respectively. The activity of CPT
II remained unaltered when compared be-
tween the groups.
5.9.3. Strength and
electrophysiology
Dynamic training did not have an effect on
the maximal voluntary force or the strength
endurance of the right knee extensors. The
slope of decline of the force remained un-
affected as well as muscle fibre conduction
velocity. The macro-EMG amplitude and
macro-EMG area also remained unaffected.
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Figure 6.
Skeletal muscle enzyme activities in the control (open bars) and the training (grey bars)
groups at baseline (0 months) and after 3 and 6 months. PHRLa=active phosphorylase,
PFK=phophofructokinase, CPT I=carnitinepalmitoyl transferase I, α-KGDH=α-ketoglu-
tarate dehydrogenase. # = p < 0.05 for difference between the changes from baseline in
the training vs the control group. The data are given as mean±SEM.
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6. DISCUSSION
This study shows in a randomized, control-
led protocol that dynamic physical training
of moderate intensity improves exercise ca-
pacity especially at submaximal work loads,
raises the anaerobic threshold and improves
NYHA functional class in patients with sta-
ble mild-to-moderate CHF. Physical train-
ing also attenuates the excessive ventilato-
ry response during exercise. Further, dem-
onstrated by HRV analysis, it improves the
sympathovagal dysbalance which may be
prognostically favourable. Training did not
change significantly the capacities of fatty
acid oxidation and the Krebs’ cycle in skel-
etal muscle assessed by the activities of the
rate-limiting enzymes of these metabolic
pathways.
6.1 Subjects
The severity of CHF and the clinical status
of the subjects in this study were very sim-
ilar to those in other studies. Patients in
NYHA functional classes II and III were
selected because their exercise capacity was
symptomatically restricted. On the other
hand, it could be assumed that, unlike
NYHA class IV patients, the remaining ex-
ercise capacity of NYHA class II and III
patients allows regular training on an indi-
vidual level. To our knowledge there are no
published studies, which have included
NYHA class IV patients (except one patient
in a strength training study by Magnusson
et al. 1996).
In contrast to other studies, the minority
of the patients had CHF secondary to ischae-
mic heart disease, which has been the case
in only two studies that have used dynamic
exercise training (Keteyian et al. 1996, De-
mopoulos et al. 1997). Since the number of
patients in the present study was small, sub-
group analyses on the response to physical
training depending on the aetiology could
not be done. No such data are available in
the literature, as far as we know.
6.2. Haemodynamic
measurements
The results of this study support the reports
that physical training does not have any del-
eterious effect on central haemodynamics
at rest. It does not cause any changes in right
atrial, right ventricular, pulmonary arterial
or pulmonary capillary wedge pressures. In
the present study, no change was seen in left
ventricular dimensions, which have not been
reported to increase in other studies, either
(Sullivan et al. 1988a). Left ventricular end-
diastolic diameter has even decreased dur-
ing high-intensity training (Hambrecht et al.
1995), although left ventricular diastolic
wall stress is significantly higher during
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high-intensity (70-80% of peak VO2) than
during low-intensity exercise (50% of peak
VO2) in patients with CHF (Demopoulos et
al. 1997). Kavanagh et al. (1996) have re-
ported a significant increase in left ventricu-
lar ejection fraction, but no other study, in-
cluding the present one, supports this find-
ing. In Kavanagh’s study, the training pro-
gramme was long, 12 months, but six out
of 21 patients did not complete it, three due
to worsening heart failure. Thus, the find-
ing is not convincing. Several studies have
demonstrated that physical training im-
proves peak cardiac output due to an in-
crease in peak heart rate and in peak stroke
volume (Coats et al. 1992, Hambrecht et al.
1995).
6.3. Symptoms
Exercise training made a significant posi-
tive impact on the NYHA functional class,
which certainly reflects the improved exer-
cise capacity. A decrease in VE during ex-
ercise also suggests that a reduced feeling
of dyspnea contributed to the effect on the
NYHA class. However, it has to be remem-
bered that this classification is a rough and
limited estimate of symptoms in CHF.
The effect of exercise training on quality
of life was not evaluated in this study. How-
ever, the change in the NYHA class is con-
cordant with those studies, which have
shown improvement in indices of specified
symptom-questionnaires (Coats et al. 1992,
Willenheimer et al. 1998). Two groups have
reported an improvement in quality of life
(Kavanagh et al. 1996, Belardinelli et al.
1999), although in two other studies the
impact of exercise training has been neutral
(Wilson et al. 1996, Willenheimer et al.
1998). This difference is possibly due to the
fact that in the first two studies the training
period was much longer, 12 and 14 months,
the two longest in the literature, while it was
3 and 4 months in the latter two. One point
makes this conclusion uncertain. The study
of Kavanagh et al. had several drop-outs as
mentioned previously. In addition, the in-
dex of quality of life used by Willenheimer
et al. was rough and non-validated. Physi-
cal training has not been reported to impair
quality of life.
6.4. Exercise capacity and
ventilatory function
The results of this study confirm that phys-
ical training improves exercise capacity in
patients with CHF. Two parameters were
used to measure exercise capacity, peak VO2
and
 
exercise duration at a constant submax-
imal work load. Peak VO2 was chosen, first-
ly, because it gives accurate information on
maximal exercise/aerobic capacity and, sec-
ondly, because it is an independent predic-
tor of mortality in CHF (Cohn et al. 1993).
The exercise capacity at constant submaxi-
mal work load was used because changes
in peak VO2 may underestimate the effect
on the submaximal working capacity of
CHF patients (Olsen et al. 1992). Further-
more, submaximal exercise capacity has
been shown to correlate better than peak VO2
with changes in the quality of life score
 
in
patients with CHF (Metra et al. 1994).
The increase in peak VO2 in this study is
comparable with the 9-18% change in oth-
er studies, in which dynamic training has
been used at moderate or low intensity
(Coats et al. 1992, Adamopoulos et al. 1993,
Belardinelli et al. 1995, Kavanagh et al.
.
.
.
.
.
.
.
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1996, Keteyian et al. 1996, Wilson et al.
1996). Thus, the response of peak VO2 to
physical training in patients with mild-to-
moderate CHF is equal to that reported in
healthy subjects of similar age (Clausen
1976). However, as in healthy subjects, with
high-intensity training, a greater improve-
ment, from 23 to 33%, has been achieved
(Sullivan et al. 1988a, Hambrecht et al.
1995, Dubach et al. 1997a).
In this study, the improvement in the ex-
ercise endurance at constant submaximal
work load was far more pronounced than that
in peak VO2. Only Sullivan et al. (1989b) have
used this test to measure the effect of physi-
cal training in CHF. They also observed a
difference, though not so pronounced, in the
response of the two parameters. The submax-
imal exercise endurance improved by 52%
and the peak VO2 by 23% in their study.
Methodologically, there is a problem with this
test as the end point is more difficult to de-
fine precisely than in the graded maximal
exercise test because the capacity limit is
approached more gradually. The rather small
change in the control group shows, however,
that the end point can be defined with suffi-
cient accuracy.
The present study is concordant with the
previous results that physical training reduc-
es the exaggerated ventilation in proportion
to carbon dioxide production during exer-
cise (Coats et al. 1992) and delays the anaer-
obic threshold (Hambrecht et al. 1995).
According to the ‘muscle hypothesis’ by
Coats (1996), both of these can be explained
by the improved function of skeletal mus-
cle but according to Wasserman et al. (1997),
the decrease in ventilation suggests prima-
rily an alleviated ventilation-perfusion mis-
match in the lungs .
This study revealed that the effect of train-
ing on exercise capacity can be maintained
by a training period of lower intensity. It has
been reported earlier that the benefit of an
8-week training period can be totally lost
during an 8-week detraining period (Coats
et al. 1990),which is supported by Meyer et
al. (1996). This is concordant with the find-
ing in healthy subjects that the increase in
mitochondrial enzyme level during an 8-12
week training period reverses in 6-8 weeks
after cessation (Holloszy et al. 1984). On
the other hand, studies, in which training
has lasted for 6-12 months, have demonstrat-
ed that most of the effect is achieved during
the first 12-16 weeks (Kavanagh et al. 1996,
Keteyian et al. 1996). Thus, training has to
be continuous, but it can be suggested that
alternation of training periods of moderate
intensity with those of lower intensity, which
exceed normal activity, improves exercise
capacity equally to constant moderately in-
tensive training in patients with CHF.
6.5. Hormones at rest
In two previous studies, more marked re-
ductions in plasma noradrenaline at rest
have been reported, although the studies
have been small like the present one (Belar-
dinelli et al. 1995, Hambrecht et al. 1995).
In the former, which was a study of low-
intensity training, a possible explanation for
the reduction would be a higher baseline
level but of importance, a comparison with
the change in the control group was not re-
ported. The latter was well performed and
the result can be explained by the very high
intensity of training. In the present study,
the lack of difference between the change
in the two groups was probably due to the
small number of patients.
Determination of plasma noradrenaline
.
.
.
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level has shortcomings in assessing sympa-
thetic activity, because it does not measure
noradrenaline release from sympathetic
nerve endings but rather the balance be-
tween noradrenaline spillover into plasma
and its clearance (Floras 1993). However,
plasma noradrenaline level correlates posi-
tively with increased sympathetic burst fre-
quency in direct microneurographic record-
ings demonstrated in patients with CHF
(Leimbach et al. 1986, Ferguson et al. 1990).
The clinically important point is that the
plasma level correlates directly with the se-
verity of CHF and mortality from it (Fran-
cis et al. 1990, Cohn et al. 1984).
The resting level of Nt-proANP was not
changed by physical training, which is in
accordance with an earlier study (European
Heart Failure Trial Group 1998). The train-
ing intensity was similar in these two stud-
ies. The result is concordant with the find-
ing that cardiac volumes and pressures,
which determine the plasma concentration
of this peptide at rest (Keller et al. 1988,
Donckier et al. 1991), also remain unaffect-
ed. However, in a recent study, plasma ANP
level at rest was lowered by high-intensity
training of four months (Braith et al. 1999).
The central haemodynamic measurements
were not performed in that study.
The stable Nt-proANP levels also support
the view that physical training is not delete-
rious for the patient because an increase in
its level reflects worse prognosis (Hall et
al. 1994). On the other hand, the unchanged
ANP level in plasma does not rule out that
its effect has changed. The attenuated re-
ceptor response, which is evident in CHF
(Eiskjaer et al. 1991), may be reversed.
Patients with CHF are at risk to develop
cardiac cachexia, which predicts mortality
independently of age, functional class, left
ventricular ejection fraction and peak VO2
in these patients (Anker et al. 1997b). Com-
pared with noncachectic patients with CHF
and healthy controls, the patients with
cachexia have higher levels of plasma no-
radrenaline, adrenaline, TNF-α, cortisol and
growth hormone (Anker et al. 1997c). Ex-
ercise stress stimulates secretion of catabolic
hormones and inhibits testosterone secretion
in healthy subjects (Kuoppasalmi et al.
1976), which may suggest induction of cat-
abolic changes in the altered hormonal sta-
tus of CHF patients.
This study shows that training with mod-
erate intensity does not induce hormonal
changes which could predispose to cachex-
ia in patients who have no signs of it. We
used free testosterone/cortisol - and DHEAS/
cortisol -ratios as estimates of the hormonal
anabolic/catabolic balance. The former ratio
has been used as an indicator of overstrain in
healthy people, showing a decrease in the
ratio (Adlercreutz et al. 1986). In CHF, the
cortisol/DHEA -ratio has previously been
shown to be highest in the subset of cachec-
tic patients and correlates strongly with the
levels of TNF-α (Anker et al. 1997a).
To our knowledge, no data exist on wheth-
er intensive training, which has been shown
to reduce symptoms and improve exercise
capacity (Hambrecht et al. 1995, Dubach et
al. 1997a), induces catabolism. It is not
probable that intensive training induces ca-
tabolism when considering the limited but
beneficial hormonal data available. The
impact of physical training on the anabolic/
catabolic balance if signs of cachexia are
already present is also unknown. It can be
assumed that the crucial point is the initial
training intensity. Evidently, it must be very
low.
.
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6.6. Hormonal response
during exercise
Little previous data exist on hormonal re-
sponse and metabolism during exercise in
patients with CHF. This study showed that
physical training increases the noradrena-
line response to maximal exercise. This has
also been shown in another study (Europe-
an Heart Failure Trial Group 1998). The
response has been shown to be reduced in
patients with CHF (Francis et al. 1982) al-
though the results are not uniform (Nicholls
et al. 1992, Riley et al. 1993). The training
effect may simply be due to the increased
level of the maximal work load, but it may
also be a reflection of an increased autonomic
responsiveness (European Heart Failure Tri-
al Group 1998). The latter could explain the
increased maximal heart rate, reversal of
chronotropic incompetence, which was also
seen in the present study.
This study did not show a decrease in plas-
ma noradrenaline level during submaximal
exercise. The result differs from that of Be-
lardinelli et al. (1995), who reported no
intergroup comparison, and Hambrecht et
al. (1995). It has been shown earlier that
plasma noradrenaline increases more at low
and moderate absolute work loads in pa-
tients with CHF when compared with
healthy subjects (Chidsey et al. 1962, Fran-
cis et al. 1982).
Patients with CHF have higher serum FFA
levels at rest and during exercise (Lommi et
al. 1998, Riley et al. 1990), which seems to
be due to increased lipolysis caused by high-
er plasma noradrenaline levels and possible
insulin resistance. In this study, serum FFA
levels during exercise were not affected by
training. This may denote an unchanged
exertional lipolysis but does not tell much
about FFA utilization.
6.7. Heart rate variability
This study demonstrates that physical train-
ing can reverse the autonomic derangement,
the sympathovagal dysbalance, observed in
CHF. The HRV analysis in frequency do-
main have shown that the absolute powers
of all components have been found to be
attenuated in CHF patients when compared
with healthy controls (Saul et al. 1988).
HRV is not a direct measure of the tone of
the autonomic nervous system but reflects
its modulation on RR-intervals (Malik et al.
1993). The HF component has generally
been accepted as an index of parasympa-
thetic modulation. The index of sympathet-
ic modulation has been controversial. We
used the LF/HF ratio because the 0.02-0.09
Hz band within the LF band reflects both
parasympathetic and sympathetic influenc-
es (Akselrod et al. 1981).
Our result that physical training enhanc-
es vagal modulation and improves sym-
pathovagal dysbalance in CHF is supported
by Adamopoulos et al. (1995). Thus, the
effect of physical training on HRV is simi-
lar in patients with CHF and in healthy peo-
ple (Mølgaard et al. 1991, Goldsmith et al.
1992) despite that, autonomic dysbalance
is a basic feature in the heart failure syn-
drome.
The data that an increase of vagal modu-
lation of HRV reduces mortality come main-
ly from studies in ischaemic heart disease
(Bigger et al. 1992; Hull et al. 1994). In
CHF, the increased risk of mortality has
clearly been shown to be associated with
SDNN (standard deviation of all normal-to-
normal RR intervals in the entire recording),
which is a time domain index of total HRV
(Nolan et al. 1998; Ponikovski et al. 1997).
In addition, an attenuation of HRV and para-
sympathetic withdrawal have also been
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shown to become worse with the progres-
sion of CHF (Szabo et al. 1995). It is note-
worthy that β-blockers and ACE-inhibitors,
which have been shown to reduce mortality
in CHF, increase HRV (Sandersson et al.
1999, Binkley et al. 1993).
Not much is known about the mechanism
involved in how physical training reverses
the autonomic derangements in CHF. Pie-
poli et al. (1996) have reported that local
training of a muscle group reduces the ex-
aggerated ergoreflex in CHF, which can lead
to concomitant attenuation of excitatory in-
put to sympathetic outflow. To our knowl-
edge, the effect of physical training on the
decreased baroreflex sensitivity, which is
regarded as the primary change in autonom-
ic derangement, has not yet been assessed
in humans.
6.8. Skeletal muscle
Fibre distribution, size and capillary density
According to this study, physical training
of moderate intensity does not affect the
percentage distribution of slow-twitch and
fast-twitch muscle fibres in patients with
CHF. Two previous studies in which low-
intensity endurance training or intensive
strength training was used have resulted in
similar outcome (Belardinelli et al. 1995,
Magnusson et al. 1996). However, all these
studies, including the present one, have been
small.
By contrast, Hambrecht et al. (1997)
found a significant increase in slow-twitch
and a corresponding decrease in fast-twitch
muscle fibre percentage distribution after
physical training. However, in healthy per-
sons it has not been demonstrated that even
strenuous exercise would cause a conver-
sion from a slow-twitch to a fast-twitch fi-
bre type but a change from glycolytic IIb
fibres to more oxidative IIa fibres occurs
(Gollnick et al. 1973; Holloszy et al. 1984).
The result of Hambrecht et al. may be ex-
plained by the substantial inter-individual
and intra-individual variation in the propor-
tion of the fibre types in vastus lateralis
muscle, which is a mixed muscle. Howev-
er, it can be speculated that hypoperfusion
with probable episodes of hypoxemia and
reperfusion together with the direct influ-
ence of neurohormonal factors on skeletal
muscle can cause a true transformation of
slow-twitch fibres to fast-twitch fibres in
CHF patients, which could be reversed by
training. Indeed, in the study of Hambrecht
et al. training was very intensive inducing a
marked increase in leg blood flow during
exercise and a 52% decrease in plasma
noradrenaline level at rest. However, the
study was small, 9 patients each in both
training and control groups, and therefore
the result is uncertain. On the contrary, the
bulk of the results so far rather suggest that
the improved exercise capacity is not de-
pendent on changes in muscle fibre size or
percentage distribution.
The importance of capillary density on the
training effect can not be evaluated on the
basis of this study because the sections of
only 7 patients in the training group and of 9
patients in the control group were analysa-
ble. Previously, intensive one-legged strength
and strength plus endurance training has been
reported to increase the capillary per fibre
ratio by approximately 50% (Magnusson et
al. 1996). On the other hand, capillary densi-
ty was not reported to change after an 8-week
low-intensity training, which improved peak
VO2 (Belardinelli et al. 1995).
Capillary density has been reported to be
normal or reduced in patients with CHF
.
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when compared with healthy subjects (Man-
cini et al. 1989, Duscha et al. 1999). Duscha
et al. further showed that the reduced capil-
lary density impairs exercise tolerance.
However, it is evident that maldistribution
of circulation within the working muscle,
independent of capillary density, is of ma-
jor importance. The significance of the lat-
ter factor was shown in a recent study on a
rat model of CHF (Kindig et al. 1999). Ac-
cording to this study, the linear density of
capillaries was increased but the percentage
of continuously red blood cell perfused cap-
illaries was reduced and the red blood cell
flux per unit tissue was markedly lower in
CHF rats compared with the controls.
Enzyme activities
To our knowledge, this is the only study that
has measured the effect of physical training
on the activities of the CPT complex and α-
KGDH in patients CHF. This study could
not demonstrate a difference between the
changes in the activity of the CPT complex,
the rate-limiting enzyme complex of fatty
acid oxidation, in the two groups. It is ap-
parent that this was due to the low statisti-
cal power of the study resulting from the
small number of patients and the variation
in the enzyme activities. The development
of the CPT I activity levels in the training
group during the study suggests that an in-
crease can be shown in groups of adequate
size. The delayed increase in VCO2/VO2 lev-
els at submaximal work loads can also be
attributed to more efficient utilization of
fatty acids during exercise. Previously, a
lower activity of CPT II has been shown in
CHF patients compared with healthy con-
trols (Näveri et al. 1997). The activity of
CPT I was not determined in that study. A
high-intensity endurance and endurance
plus strength training have previously been
reported to increase the activity of 3-hy-
droxyacyl-CoA-dehydrogenase (Magnus-
son et al. 1996) but this enzyme does not
reflect the maximal capacity of fatty acid
oxidation. The comparison of the change
with that in the control leg was not report-
ed, either.
The present study did not show an in-
crease in the activity of α-KGDH, the rate-
limiting enzyme of the Krebs cycle, the ac-
tivity of which is also lower in patients with
CHF than in healthy subjects (Näveri et al.
1997). We can speculate that the intensity
of exercise was not high enough to increase
the activity of α-KGDH. It is likely that the
capacity of the Krebs cycle is related to peak
VO2. Accordingly, training did not cause a
marked increase in peak VO2. However, it
is obvious that with high-intensity training
a significant increase in the capacity of the
Krebs cycle will be achieved. Accordingly,
Hambrecht et al. (1995) showed that a 6-
month training period with an intensity cor-
responding to 70% of the peak VO2 raised
the volume density of cytochrome oxidase
positive mitochondria by 41% in skeletal
muscle, which refers to improved aerobic
metabolism. Peak VO2 improved by 33%.
The activities of different mitochondrial
enzymes were not determined. In another
study, a high-intensity endurance and endur-
ance plus strength training have raised the
activity of citrate cynthase (Magnusson et
al. 1996) but the activity of this enzyme does
not reflect the maximal capacity of the
Krebs cycle (Newsholme 1980) and further,
the comparison of the change with the con-
trol leg was not reported.
The mechanism of the increase in the ac-
tivity of PFK in the present study is not clear.
Previously, its activity in patients with CHF
.
.
.
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has been reported to be similar to or less
than that in healthy subjects (Sullivan et al.
1990, Näveri et al. 1997, Sylvén et al. 1991).
In healthy subjects, high-intensity training
has been shown to enhance the activity of
PFK (Gollnick et al. 1973). In CHF the data
about the effect on anaerobic glycolysis is
very scanty. In one study, a reduced activity
of PFK rose during 5-6 weeks’ treatment
with captopril in patients who were in the
NYHA III functional class (Sylvén et al.
1991), which may reflect a specific effect
of ACE-inhibitors and/or increased physi-
cal activity after a reduction in symptoms.
The finding of the present study suggests
that, although the training intensity was
moderate, it could have anaerobic periods,
particularly in the beginning, during the su-
pervised training. The partial reversal of the
increase in PFK activity during the home-
based training, which did not reach the same
intensity, supports this view. These results
may also reflect a faster response of the gly-
colytic pathway to exercise in patients with
CHF.
Strength and electrophysiology
The present study showed that dynamic
training of moderate intensity does not im-
prove maximal voluntary strength or
strength endurance in the trained muscle
group. On the basis of the previous studies,
strength training should be included in the
training protocol in order to improve mus-
cle strength in CHF patients (Koch et al.
1992, Magnusson et al. 1996). In the study
by Magnusson et al. (1996), the isometric
strength in the knee extensors improved by
40% during an 8-week training period but a
comparison with the control leg was not re-
ported. Thus, it is likely that a combination
of dynamic training with strength training
of various muscle groups results in a better
exercise capacity with a lower symptom lev-
el than either of them alone.
In this study, changes in muscle or nerve
electrophysiology were not found. This sup-
ports previous reports, showing that mus-
cle fatigue in patients with CHF is not
caused by impaired central motor drive or
an abnormality of neuromuscular junction
transmission (Minotti et al. 1992, Harridge
et al. 1996).
6.9. Mechanism behind
improved exercise capacity
The reduced exercise capacity observed in
CHF patients is attributed to decreased car-
diac output, impaired vasodilation and per-
fusion of the working muscles, muscle at-
rophy and impaired aerobic capacity of
muscle metabolism. Increased ventilatory
work also contributes.
This study suggests that the beneficial
effects of physical training of moderate in-
tensity on skeletal muscle are a major fac-
tor behind the improved exercise endurance
in patients with CHF. Increased anaerobic
threshold and a delayed increase in the res-
piratory exchange ratio during exercise re-
fer to improved aerobic capacity in skeletal
muscle cells, although changes in the ca-
pacity of fatty acid oxidation and the Krebs
cycle could not be demonstrated. The re-
duction in minute ventilation during exer-
cise is a contributing factor through a likely
decrease in ventilatory work and dyspnea.
The role of circulation in the training ef-
fect, especially on submaximal exercise ca-
pacity, is still incompletely known. Studies
have shown only an increasing trend (Ham-
brecht et al. 1995) or no change at all (Sul-
livan et al. 1988a) in leg blood flow, meas-
54
ured from the femoral vein, at submaximal
work loads after high-intensity training. This
does not explain the markedly improved
submaximal exercise capacity. However,
measuring leg blood flow from the femoral
vein does not tell about possible changes in
the distribution of circulation within the
working muscles, and a recent experimen-
tal study shows that important changes oc-
cur in the distribution of nutritive flow into
the capillaries in CHF (Kindig et al. 1999).
Endothelial dysfunction, which is well
established in CHF (Drexler et al. 1993), is
known to have a significant role in redis-
tributing blood flow during exercise, ad-
versely affecting exercise capacity (Drex-
ler 1998). An earlier study showed that a
training protocol confined to one forearm
of CHF patients enhanced endothelium-de-
pendent blood flow in the forearm but not
in the contralateral extremity, showing that
local factors account for the beneficial ef-
fect (Hornig et al. 1996). Recently, an im-
provement in endothelial dysfunction in the
femoral artery after physical training with
cycle ergometry has been demonstrated
(Hambrecht et al. 1998).
Thus, a significant enhancement in max-
imal exercise capacity and peak VO2 likely
calls for increased cardiac output, more ef-
fective nutritive perfusion and improved
skeletal muscle aerobic metabolism.
6.10.Safety
This study with no drop-outs and a high at-
tendance at training sessions strengthens the
view that physical training is safe for pa-
tients meeting the inclusion criteria used,
although the size of the study does not al-
low a firm conclusion. Although the total
percentage of drop-outs in other studies has
varied from 0 to 29%, there has been no dif-
ference in this respect between the training
and control groups. However, whether pa-
tients with significant arrhythmias or mani-
fest cardiac cachexia can train safely is still
unknown. There is only one report of a sub-
group of 6 patients with repetitive ventricu-
lar arrhythmias who went safely through a
4-week training program and gained bene-
fits in exercise capacity comparable with
patients who had no significant arrhythmi-
as (Hambrecht et al. 1995).
6.11.Prognosis
This study indirectly suggests that physical
training may be prognostically favourable
for patients with CHF. HRV increased and
shifted towards vagal predominance and
peak VO2 increased after physical training.
These are beneficial changes in independ-
ent predictors of mortality (Nolan et al.
1998, Cohn et al. 1993), although little data
are available on whether modulation of these
parameters affects mortality. However, this
favourable prognostic view is strongly sup-
ported by the recent results of a randomized
study of 99 patients by Belardinelli et al.
(1999), which showed that a 14-month ex-
ercise training period significantly reduced
mortality and the need for hospital readmis-
sion during a 5-year follow-up period.
6.12.Limitations of the study
The main limitation of this study was the
small number of patients. The analysis of
the hormonal and enzymatic data was fur-
ther affected by the wide variation in the
hormone and enzyme levels. On the other
.
.
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hand, the estimation of the sufficient size of
the groups was hindered by the fact that only
two uncontrolled studies (16 and 18 pa-
tients) and one with a crossover protocol (11
patients), which reported beneficial effect
on exercise capacity, had been published
before this study began. The openness of a
study is also always a limitation. However,
in this kind of study it is difficult to avoid.
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7. SUMMARY AND CONCLUSIONS
Patients and methods
The study population was 27 patients (26
men and 1 woman) with CHF in NYHA
functional classes II or III, who had been
stable for at least 3 months. They were ran-
domized to training (n = 12) or control (n =
15) groups. The training group took part in
moderate-intensity training with a cycle er-
gometer under supervision for 3 months
followed by a home-based training period
for another 3 months (walking, cycling, row-
ing). The control group was advised not to
change the previous physical activity.
Haemodynamic measurements were per-
formed with right heart catheterization at
rest and transthoracic echocardiography.
Exercise capacity was determined by two
tests on a cycle ergometer. A graded maxi-
mal exercise test was performed with respi-
ratory gas analysis and exercise endurance
was measured by cycling time at constant
submaximal work load.
Twenty-hour ambulatory ECG-recordings
were registered in patients in sinus rhythm
to assess HRV in the frequency domain as
an indicator of autonomic balance. In addi-
tion, the resting plasma levels and exertion-
al response of noradrenaline, adrenaline,
cAMP and Nt-proANP were assessed. The
influence of training on catabolic and ana-
bolic hormones was assessed both at rest and
during exercise.
Background
Previously, CHF has been regarded purely
as a disease of a weakened heart pump. Ac-
cordingly, the patients have been urged to
restrain from exercise to avoid further stress
on the heart. However, CHF now appears to
be a clinical syndrome affecting many or-
gan systems. The cardinal pathophysiolog-
ic mechanism, regardless of aetiology, is
neurohormonal activation, firstly adaptive,
trying to restore the balance of circulation,
but which in the long term, turns maladap-
tive, contributing to increasing abnormali-
ties in the heart and periphery. In particular,
peripheral abnormalities are seen in circu-
lation and ventilatory function during exer-
cise and in skeletal muscle. Increasing dys-
pnea and muscle fatigue also promote sed-
entary behaviour, which leads to decondi-
tioning, which may further worsen the ex-
ercise capacity. This study was performed
to test the hypothesis that physical training
reduces the symptoms and improves exer-
cise capacity in patients with CHF without
having any harmful effects on the heart func-
tion. A further hypothesis was that physical
training reverses the abnormalities in the
periphery and has beneficial effects on prog-
nostic factors.
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Skeletal muscle biopsies were taken from
vastus lateralis muscle. Microscopic sec-
tions were prepared for assessment of fibre-
type distribution, size and capillary density.
The activities of rate-limiting enzymes of
glycogenolysis, glycolysis, fatty acid oxi-
dation and the Krebs’ cycle were deter-
mined. Strength, strength endurance and
electrophysiology of right knee extensors
were assessed.
Results
Compliance to training was high with no
drop-outs. Only one individual training ses-
sion was discontinued because of ventricu-
lar ectopies. Training did not cause any pres-
sure changes in the right atrium, right ven-
tricle and pulmonary circulation, nor in the
left ventricular diameters and systolic func-
tion at rest during the supervised training
period.
Training improved peak VO2, exercise
endurance at constant submaximal work
load (85% of the peakVO2 at baseline),
anaerobic threshold and the NYHA func-
tional class significantly compared with the
control group. The most marked improve-
ment occurred in exercise endurance at con-
stant submaximal work load which almost
doubled. Training reduced minute ventila-
tion, VE/VCO2 and delayed the rise of
VCO/VO2 during exercise. The effects, seen
after the supervised training period, were
preserved during the home-based training
period, which was estimated to have been
lower in intensity on the basis of patient in-
terviews.
HRV analysis revealed an increase in the
HF component, an indicator of vagal mod-
ulation and a decrease in the LF/HF ratio,
an indicator of sympathetic modulation in
the training group compared with the con-
trols.
Training did not have an influence on
plasma noradrenaline and plasma ANP lev-
els, but the exertional response of noradren-
aline to graded maximal exercise increased.
The anabolic/catabolic balance, measured
by the free testosterone/cortisol - and DHEAS/
cortisol -ratios, remained unchanged in both
groups.
Training increased the activity of PFK,
the rate-limiting enzyme of glycolysis, in
skeletal muscle. However, the activities of
CPT I and CPT II, which form the rate-lim-
iting enzyme complex of fatty acid oxida-
tion, and those of α-KGDH and PHRL, the
rate-limiting enzymes of the Krebs’ cycle
and glycogenolysis, respectively, did not
change in comparison with the control
group. The percentage distribution of slow-
twitch and fast-twitch fibres did not change
in either group, nor did the capillary densi-
ty around these fibers. This type of training
did not have an effect on the maximal vol-
untary strength and strength endurance of
knee extensors. Electrophysiological param-
eters also remained unchanged in both
groups.
Conclusions
Dynamic physical training of moderate in-
tensity reduces symptoms and improves
exercise capacity in patients with stable
mild-to-moderate CHF. This is achieved
without any effect on central haemodynam-
ics or left ventricular size and systolic func-
tion at rest. The training effect is seen espe-
cially at submaximal work loads. Training
reduces the excessive ventilatory response
during exercise and raises the anaerobic
threshold.
.
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Physical training attenuates the derange-
ment in the autonomic nervous system,
which was demonstrated by an increase in
the parasympathetic modulation and a de-
crease in the sympathetic modulation of
heart rate variability. However, a change in
plasma noradrenaline level at rest was not
observed.
Training with this intensity and duration
does not have an adverse effect on the ana-
bolic/catabolic balance in non-cachectic
patients with CHF.
Training increased the capacity of glyco-
lysis but did not show an improvement in
the capacity of fatty acid oxidation and the
Krebs’ cycle in skeletal muscle cells to pro-
duce aerobic energy. Training did not induce
any changes in skeletal muscle histology.
The small number of the patients restricts
the statistical power of this study.
The main future tasks and open questions
concerning physical training in patients
with CHF:
1. The effect on mortality and the need of
hospital readmission should be evaluated in
a large multicenter trial.
2. What is the mechanism of the proba-
ble reduction in mortality, slower progres-
sion of heart failure or prevention of sud-
den death?
3. The effect on neurohormonal and cy-
tokine activation and skeletal muscle me-
tabolism and histology should be evaluated
in a study of adequate size.
4. Are the results applicable to patients
with severe CHF?
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